Please assess the completion status of the following clinical trial:

Trial Title: QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
ENTRY CRITERIA:~DISEASE CHARATERISTICS:~* Confirmed diagnosis of relapsed/refractory multiple myeloma after treatment with at least two different previous regimens.~  * Refractory disease is defined as progressive disease while on therapy or progression within 60 days of therapy.~ * Progressive disease is defined by a 25% increase from the lowest response value in specified tests.~* Measurable disease as defined by at least one of the following:~  * Serum M-protein ≥ 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)~ * Urine M-protein ≥ 200mg/24hours~ * Serum free light chains ≥ 10 mg/dL and abnormal kappa/lambda ratio~PRIOR/CONCURRENT THERAPY:~* No anti-myeloma treatments within 28 days before the start of study treatment.~* Must have recovered from side effects of prior treatments.~PATIENT CHARACTERISTICS:~Age~• ≥ 18 years~Performance Status~• ECOG 0, 1, or 2~Bone Marrow Reserve~* Absolute neutrophil count (AGC/ANC) ≥ 1,000/uL~* Platelets ≥ 30,000/uL~* Hemoglobin ≥ 8g/dL~Renal Function~• Glomerular Filtration Rate (GFR) \> 45mL/min/1.73m\^2~Hepatic Function~* Total bilirubin ≤ 2.0 X ULN~* AST, ALT, ALP ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver metastases exist)~Cardiovascular~* No congestive heart failure \< 6 months~* No unstable angina pectoris \< 6 months~* No myocardial infarction \< 6 months~* No history of ventricular arrhythmias~* No history of supraventricular arrhythmias~* No NYHA Class \> II CHF~* Normal Transthoracic Echocardiogram (TTE) is required for patients with history of EKG abnormalities, CHF, coronary artery disease or other cardiac disease, or with a history of having received adriamycin or doxorubicin~* Patients with a left ventricular ejection fraction (LVEF) of less than 50% will be excluded from study entry~Pulmonary~• Normal clinical assessment of pulmonary function~Other~* Negative serum pregnancy test if female and of childbearing potential~* Women who are not pregnant or nursing~* Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study~* No known autoimmune disease other than corrected hypothyroidism~* No known prior organ allograft or allogeneic transplantation~* Not HIV positive~* No history or evidence of uncontrollable CNS disease~* No psychiatric illness/social situation~* No other illness that in the opinion of the investigator would exclude the subject from participating in the study~* Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations~* Active systemic infection requiring parenteral antibiotic therapy.~* No ongoing chronic systemic steroid therapy required.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALT-801 0.04mg/kg (Type: EXPERIMENTAL): None
- ALT-801 0.06mg/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy